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Purpose/objectives. To compare the results in term of biochemical disease-free survival (BDFS), disease free survival (DFS), overall
survival (OS) and toxicity in patients (pts) with prostate cancer (PCa) with at least a 15% likelihood of lymph node involvement
treated with whole pelvic radiotherapy (WPRT) or prostate-only radiotherapy (PORT) using a Spanish prostate data base (RECAP).
Materials/methods. Multicenter retrospective comparative study of 1843 pts with intermediate, high and very high risk PCa accord-
ing NCCN criteria without nodes invasion, treated with radical radiotherapy to pelvis (885) or prostate only (958) using RECAP data
base (August 1993–September 2009). Baseline characteristic of WPRT vs PORT differed signiﬁcantly in age, initial PSA, Gleason,
Tumor stage, total radiation dose, and number of pts treated with androgen deprivation therapy (ADT) and duration of ADT.
Phoenix deﬁnition was used for biochemical failure. Kaplan–Meier curves have been used for the statistical analysis of survival
and the long-rank test for the comparison of the survivals. Prognostic factors such as age, tumor stage, Gleason score and ADT
have been related to BDFS, DFS and OS using Cox regression. Treatment-related toxicity was assessed using Radiation Therapy
Oncology group and the National Cancer Institute’s Common Terminology Criteria for Adverse Events guidelines.
Results. Themedian follow-upwas 83month forWPRT and 79months for PORT.WPRTpatients hadmore advanced and aggressive
disease at baseline (p< .0001). The 10-year BDFS, DFS and OS for WPRT were 54%, 72% and 72% respectively and for PORT were 59%
(p=0.86), 90% (p=0.0007) and 79% (p=0.22) respectively. Patients undergoing WPRT had increased acute genitourinary (p<0.0001)
and gastrointestinal toxicity (p<0.0001), and late genitourinary (p=0.02) and gastrointestinal toxicity (p=0.03).
Conclusion. According to our results WPRT was not associated with an improvement in BDFS, DFS and OS and results in a greater
incidence of acute and late toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.806
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Introduction. 3T functional (diffusion-weighted and dynamic contrast enhanced) magnetic resonance imaging (MRI) has been
proved useful in the management of prostate cancer. However, in clinical practice, it’s not universally used.
Objectives. To evaluate in how many patients, the staging by 3T functional MRI changed our treatment.
Methods. Between January 2009 and December 2012, 143 patients were evaluated (104 patients were treated with radical radio-
therapy (RT) and 39 received postoperative RT). 3T functional MRI was performed after transrectal ultrasound (TRUS) guided
biopsy and before starting RT. We deﬁned three recurrence risk groups according to outcomes of MRI and following the National
Comprehensive Cancer Network (NCCN) criteria. We change the radiation treatment (planning target volume (PTV) and doses)
and hormonal therapy (HT) by MRI ﬁndings.
Results. Radical RT: MRI detected prostate tumor in 98% of patients. By digital rectal examination (DRE) and TRUS the tumor
was evident only in 24% of patients. In 67.3% of patients of the MRI results agreed with TRUS guided prostate biopsy performed
previously. In 25% of patients there was a change in the risk group of recurrence based on the outcomes of MRI. 19.2% low risk
patients became intermediate risk and 4.8% intermediate risk became high risk. One patient, who was initially included in low
